SCHEMBL6183336

SCHEMBL6183336

C/C(=C\c1ccc(-c2cccc(CNC(=O)c3ccccc3)c2)cc1)C(=O)O

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SENP1 Q9P0U3 6/20 0.55
CFD P00746 1/20 0.53
EGFR P00533 2/20 0.52
EPHX2 P34913 2/20 0.51
NR1H4 Q96RI1 2/20 0.51
SENP2 Q9HC62 1/20 0.51
ERN1 O75460 1/20 0.50
SMN1; SMN2 Q16637 1/20 0.50
HDAC1 Q13547 2/20 0.48
HDAC3 O15379 1/20 0.48
HDAC4 P56524 1/20 0.48
HDAC7 Q8WUI4 1/20 0.48
HDAC2 Q92769 1/20 0.48
HDAC10 Q969S8 1/20 0.48
HDAC11 Q96DB2 1/20 0.48
HDAC8 Q9BY41 1/20 0.48
HDAC6 Q9UBN7 1/20 0.48
HDAC9 Q9UKV0 1/20 0.48
HDAC5 Q9UQL6 1/20 0.48
AOC3 Q16853 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6183341 1.00 SENP1 (0.55) SENP1CFDEGFREPHX2NR1H4
SCHEMBL4363907 0.84 AKR1C3 (0.43) SENP1CFDSENP2ERN1HDAC1
SCHEMBL4363911 0.84 AKR1C3 (0.43) SENP1CFDSENP2ERN1HDAC1
SCHEMBL6183707 0.84 ERN1 (0.61) SENP1CFDEGFREPHX2NR1H4
SCHEMBL5726547 0.83 CFD (0.71) SENP1CFDEGFREPHX2NR1H4
SCHEMBL5943942 0.79 HDAC6 (0.76) SENP1CFDEGFREPHX2NR1H4
SCHEMBL532624 0.76 AKR1C3 (0.77) SMN1; SMN2HDAC2
SCHEMBL532625 0.76 AKR1C3 (0.77) SMN1; SMN2HDAC2
SCHEMBL6184231 0.75 MAOA (0.53) SENP1CFD
SCHEMBL6184236 0.75 MAOA (0.53) SENP1CFD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6927228-B2 Biphenyl compounds usefuf in treatment of human and veterinary medicines such as dermatology, cardivovascular diseases, immune diseases or diseases associated with lipid metabolisms, or in cosmetic formulation GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) 2005-08-09 US disclosed
EP-1309575-B1 BIPHENYL DERIVATIVES AND THEIR USE AS PPAR-GAMMA RECEPTOR ACTIVATORS GALDERMA RES & DEV (FR) 2005-06-08 EP disclosed
US-20040039038-A1 Biaromatic compound activators of PPARy-type receptors GALDERMA RESEARCH & DEVELOPMENT S.N.C. (FR) 2004-02-26 US disclosed
EP-1309575-A1 BIPHENYL DERIVATIVES AND THEIR USE AS PPAR-GAMMA RECEPTOR ACTIVATORS Galderma Research & Development (FR) 2003-05-14 EP disclosed
WO-2002012210-A9 BIPHENYL DERIVATIVES AND THEIR USE AS PPAR-GAMMA RECEPTOR ACTIVATORS GALDERMA RES & DEV (FR) 2002-04-18 WO disclosed
WO-2002012210-A1 BIPHENYL DERIVATIVES AND THEIR USE AS PPAR-GAMMA RECEPTOR ACTIVATORS GALDERMA RESEARCH & DEVELOPMENT (FR) 2002-02-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040039038-A1 Biaromatic compound activators of PPARy-type receptors PPARG, PPARA, PPARD SENP1 4246/4885CFD 4431/4885EGFR 1435/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.